주 메뉴 바로가기 본문 바로가기 하단 바로가기

Company

Celltrion, leading the Korean biopharmaceutical industry.

About Us

A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business.

Vision

We aim to become a global pharmaceutical company that promotes health and welfare for all by developing next-generation biopharmaceutical and small molecule pharmaceutical products.

Core Values
Creativity
We solve problems by thinking outside the box.
Principle
We value principles, faith and trust.
Challenge
We meet challenges head-on and continuously look for challenges others are reluctant to take on.
Global No. 1
We emphasize top-tier expertise and competitiveness to lead the global market.
At a Glance
World’s First

Antibody
Biosimilar

No. of Employees

1,942

as of July 2019

Revenue

USD 818 million

in 2018

Total Remsima exports

USD 2.2 billion

as of March 2019

Sales Permits in

More than 90 countries

as of 2019

Production Capacity

190,000 liters

as of 2019